(Q35041900)

6 August 2017

0 references

1 reference

title

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. (English)

1 reference

6 August 2017

2

T Poynard

1 reference

6 August 2017

R P Myers

1

1 reference

6 August 2017

publication date

1 January 2002

1 reference

Cochrane Database of Systematic Reviews

6 August 2017

published in

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

CD003617

1 reference

Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Dose increase augments response rate to interferon-alpha in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Human leucocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Re-treatment of chronic hepatitis C with consensus interferon .

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Therapy of hepatitis C: re-treatment with alpha interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Interferon retreatment of nonresponders with HCV-RNA-positive chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Retreatment with interferon in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Retreatment with interferon-alpha of chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Meta-analyses of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003617

10.1002/14651858.CD003617

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference